Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Patients with relapsed/refractory (R/R) mature T- and natural killer (NK)–cell neoplasms lack effective treatments after failure of standard therapies. This phase 2 study evaluated the efficacy and safety of the programmed cell death protein 1 inhibitor tislelizumab in these patients. Seventy-seven...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachy, Emmanuel, Savage, Kerry J., Huang, Huiqiang, Kwong, Yok-Lam, Gritti, Giuseppe, Zhang, Qingyuan, Liberati, Anna Marina, Cao, Junning, Yang, Haiyan, Hao, Siguo, Hu, Jianda, Zhou, Keshu, Petrini, Mario, Russo, Filomena, Zhang, Huilai, Sang, Wei, Ji, Jie, Ferreri, Andrés José María, Damaj, Gandhi Laurent, Liu, Hui, Zhang, Wei, Ke, Xiaoyan, Ghiggi, Chiara, Huang, Sha, Li, Xiaotong, Yao, Hui, Paik, Jason, Novotny, William, Zhou, Wenxiao, Zhu, Hongjie, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440460/
https://www.ncbi.nlm.nih.gov/pubmed/37276067
http://dx.doi.org/10.1182/bloodadvances.2022009575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440460/
https://www.ncbi.nlm.nih.gov/pubmed/37276067
http://dx.doi.org/10.1182/bloodadvances.2022009575

Ejemplares similares